Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs

Current Treatment Options in Allergy

Volumn 2, Issue 3, 2015, Pages 268-285

  Giavina Bianchi, Pedro ^a,b   Aun, Marcelo Vivolo ^b   Galvão, Violeta Régnier ^a,b   Castells, Mariana ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse drug reaction; Anaphylaxis; Aspirin; Drug hypersensitivity reaction; Monoclonal antibodies; Platinum compounds; Protocol; Rapid drug desensitization; Taxanes; lactam antibiotics

Indexed keywords

EID: 84973146235     PISSN: None     EISSN: 21963053     Source Type: Journal    
DOI: 10.1007/s40521-015-0060-2     Document Type: Review

References (68)

1. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. J Allergy Clin Immunol. 2004;113:832–6. Nomenclature standardization for allergy held by the World Allergy Organization. DOI: 10.1016/j.jaci.2003.12.591
2. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. 2014;69:420–37. Most recent consensus addressing drug allergy. DOI: 10.1111/all.12350
3. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity—a consensus statement. Allergy. 2010;65:1357–66. Main consensus addressing rapid drug desensitization. DOI: 10.1111/j.1398-9995.2010.02441.x
4. Castells MC. Anaphylaxis to chemotherapy and monoclonal antibodies. Immunol Allergy Clin North Am. 2015;35:335–48. DOI: 10.1016/j.iac.2015.01.011
5. Joint Task Force on Practice Parameters: American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105:259–73. Important consensus addressing drug allergy. DOI: 10.1016/j.anai.2010.08.002
6. Castells MC, Tennant NM, Sloane DE, Ida Hsu F, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574–80. First large case series published in rapid desensitization with chemotherapy. A major protocol of desensitization to chemotherapy. DOI: 10.1016/j.jaci.2008.02.044
7. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259–66. First large case series published in rapid desensitization with monoclonal antibodies. A major protocol of desensitization to monoclonal antibodies. DOI: 10.1016/j.jaci.2009.09.009
8. Sancho-Serra MDC, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol. 2011;41:1004–13. DOI: 10.1002/eji.201040810
9. Andrews NL, Pfeiffer JR, Martinez AM, Haaland DM, Davis RW, Kawakami T, et al. Small, mobile FcɛRI receptor aggregates are signaling competent. Immunity. 2009;31:469–79. DOI: 10.1016/j.immuni.2009.06.026
10. Oka T, Rios EJ, Tsai M, Kalesnikoff J, Galli SJ. Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells. J Allergy Clin Immunol 2013;:1–27.
11. Novak N, Mete N, Bussmann C, Maintz L, Bieber T, Akdis M, et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012;130:1153–1158.e2. DOI: 10.1016/j.jaci.2012.04.039
12. Castells MC, Klickstein LB, Hassani K, Cumplido JA, Lacouture ME, Austen KF, et al. gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol. 2011;2:1–8.
13. Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs. 2014;28:133–44. Critical review regarding the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. DOI: 10.1007/s40259-013-0066-x
14. Sullivan TJ, Yecies LD, Shatz GS, Parker CW, Wedner HJ. Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol. 1982;69:275–82. A major protocol of penicillin desensitization. DOI: 10.1016/S0091-6749(82)80004-3
15. Giavina-Bianchi P, Caiado J, Picard M, Pur Ozyigit L, Mezzano V, Castells M, et al. Rapid desensitization to chemotherapy and monoclonal antibodies is effective and safe. Allergy. 2013;68:1482–4. DOI: 10.1111/all.12228
16. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68:853–61. DOI: 10.1111/all.12105
17. Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371–6. Important severity grading of anaphylaxis. DOI: 10.1016/j.jaci.2004.04.029
18. Castells Guitart MC. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. J Investig Allergol Clin Immunol. 2014;24:72–9.
19. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141.
20. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs. 2010;2010.
21. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer. 2008;18:615–20. DOI: 10.1111/j.1525-1438.2007.01063.x
22. Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301–7. DOI: 10.1002/cncr.11379
23. Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41:2262–7. DOI: 10.1016/j.ejca.2005.06.021
24. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1:494–500. Platin specific IgE may be a valuable diagnostic test. DOI: 10.1016/j.jaip.2013.06.002
25. Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001;61:129–33. DOI: 10.1159/000055363
26. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84:378–82. DOI: 10.1006/gyno.2001.6519
27. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45:492–8. DOI: 10.1016/j.ejps.2011.09.016
28. Prieto-Garcia A, de la Pineda Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol. 2010;20:170–1.
29. Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão V, Castells MC. Added value of skin testing in hypersensitivity reactions to taxanes. J Allergy Clin Immunol. 2014;133:AB152. DOI: 10.1016/j.jaci.2013.12.557
30. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84:420–5. DOI: 10.1006/gyno.2001.6546
31. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102–5.
32. Kotsovilis S, Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol. 2014;1060:37–59. DOI: 10.1007/978-1-62703-586-6_3
33. Li GN, Wang SP, Xue X, Qu XJ, Liu HP. Monoclonal antibody-related drugs for cancer therapy. Drug Discov Ther. 2013;7:178–84.
34. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010;16:4331–8. DOI: 10.1158/1078-0432.CCR-10-0570
35. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011;106:547–8. DOI: 10.1016/j.anai.2011.03.014
36. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014;19:228–34. DOI: 10.1634/theoncologist.2013-0286
37. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28. DOI: 10.1056/NEJMoa063842
38. Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol. 2010;24:495–6. DOI: 10.1111/j.1468-3083.2009.03437.x
39. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250–6.
40. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30:41–4. DOI: 10.1016/j.jemermed.2005.01.033
41. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol. 2007;120:972–3. DOI: 10.1016/j.jaci.2007.06.038
42. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015;3:175–85. Enlightening review regarding hypersensitivity reactions to monoclonal antibodies. DOI: 10.1016/j.jaip.2014.12.006
43. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83:1551–5. Importance of serum tryptase measurement in the diagnosis of anaphylaxis. DOI: 10.1172/JCI114051
44. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology. 1991;75:945–9. DOI: 10.1097/00000542-199112000-00004
45. Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127:587–593.e22. Main guideline addressing anaphylaxis. DOI: 10.1016/j.jaci.2011.01.038
46. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57:45–51.
47. Bavbek S, Ataman S, Akinci A, Castells M. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 2015; in press.
48. Mirakian R, Leech SC, Krishna MT, Richter AG, Huber PAJ, Farooque S, et al. Management of allergy to penicillins and other beta-lactams. Clin Exp Allergy. 2015;45:300–27. DOI: 10.1111/cea.12468
49. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am. 2010;94:805–20. Enlightening review regarding hypersensitivity reactions to beta-lactam. DOI: 10.1016/j.mcna.2010.04.006
50. Doña I, Barrionuevo E, Blanca-Lopez N, Torres MJ, Fernandez TD, Mayorga C, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol. 2014;24:143–53.
51. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol. 1987;80(3Pt1):314–9. DOI: 10.1016/0091-6749(87)90037-6
52. Legere III HJ, Palis RI, Bouza TR, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009;8:418–24. DOI: 10.1016/j.jcf.2009.08.002
53. Wendel GDJ, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312:1229–32. A major protocol of penicillin desensitization. DOI: 10.1056/NEJM198505093121905
54. Scherer K, Brockow K, Aberer W, Gooi JHC, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions—an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68:844–52. DOI: 10.1111/all.12161
55. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68:1219–32. Main classification of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. DOI: 10.1111/all.12260
56. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphylaxis. J Allergy Clin Immunol Pract. 2014;2:414–20. Recognition of nonsteroidal anti-inflammatory drugs as a major cause of anaphylaxis. DOI: 10.1016/j.jaip.2014.03.014
57. Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15:508. DOI: 10.1007/s11882-014-0508-7
58. Widal F, Abrami P, Lermoyez J. Anaphylaxie et idiosyncrasie. 1992 [Anaphylaxis and idiosyncrasy. 1992]. Allergy Proc. 1993;14:373–6. discussion 371–2. DOI: 10.2500/108854193778774065
59. White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33:211–22. Leading protocols of aspirin desensitization. DOI: 10.1016/j.iac.2012.10.013
60. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011;3:3–10. DOI: 10.4168/aair.2011.3.1.3
61. Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134:883–90. DOI: 10.1016/j.jaci.2014.02.041
62. Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133:286–7.e1–9. DOI: 10.1016/j.jaci.2013.11.016
63. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97:688–93. DOI: 10.1016/S1081-1206(10)61101-5
64. Chapman AR, Rushworth GF, Leslie SJ. Aspirin desensitization in patients undergoing percutaneous coronary intervention: a survey of current practice. Cardiol J. 2013;20:134–8. DOI: 10.5603/CJ.2013.0025
65. Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol. 2008;101:786–9. DOI: 10.1016/j.amjcard.2007.10.045
66. Lee JKT, Tsui KL, Cheung CY, Chau CH, Chan HL, Wu KL, et al. Aspirin desensitisation for Chinese patients with coronary artery disease. Hong Kong Med J. 2013;19:207–13. DOI: 10.12809/hkmj133717
67. De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol. 2013;167:561–3. DOI: 10.1016/j.ijcard.2012.01.063
68. McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol. 2013;36:25–30. DOI: 10.1002/clc.22054